A recent medical study has revealed the development of an innovative gene therapy injection that could represent a major breakthrough in the management of type 1 diabetes, aiming to help the body produce insulin naturally and potentially reduce reliance on daily injections.
The new injection, known as KRIYA-839, is based on gene therapy technology that delivers genetic instructions into muscle cells, enabling them to continuously and regulatedly produce insulin without directly modifying the patient’s DNA.
According to researchers, the full effects of the treatment may take between two to three months to appear, with patients being monitored for up to one year to assess the therapy’s safety and effectiveness.
This trial is considered one of the first of its kind globally, with researchers noting that it represents a long-awaited advancement, particularly for patients who struggle to control blood sugar levels despite using modern insulin delivery systems.
Early animal studies, including tests on mice and dogs, have shown promising results, with improved blood sugar stability and effects that may last for several years, suggesting long-term potential for this approach.
However, experts caution against labeling the treatment as a definitive cure, emphasizing that it is still in the experimental stage and may function more as a functional therapy that reduces insulin dependence rather than completely eliminating the disease.
For more details and latest news follow Misr Connect
